Conditional approval: Japan lowers the bar for regenerative medicine products.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25842975.
- Also identified by DOI 10.1016/j.stem.2015.03.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A new system for conditional approval of regenerative medicine products will allow products of undetermined efficacy to enter the Japanese market. The potential scientific, economic, and ethical implications of this program highlight the need for further discussion and refinement.
Medical subject headings
- Device Approval
- Drug Approval
- Health Care Sector
- Regenerative Medicine
- Stem Cell Transplantation